/

LXEO

Lexeo Therapeutics, Inc.After hours

2.63−0.11 −4.01%USD

NasdaqGM · as of Oct 14, 16:00 ET · 15m delayAfter hours 2.63 0.00%

Open

2.70

Prev close

2.74

Day range

2.562.79

52-week range

2.5610.99

Volume

1.92M1.57×

Mkt cap

215.89M

P/E ttm

—

Fwd P/E

-1.93

EPS ttm

-1.02

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−76.07%

Price Chart

Yahoo Finance · delayed

LXEOOct 14, 2026O 2.70H 2.79L 2.56C 2.63−0.11 (−4.01%)Vol 1.92M

SMA 504.22
SMA 2005.60

1Y change −67.93% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

LXEO Lexeo Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −20.54%
1 month: −37.53%
3 months: −44.51%
6 months: −61.32%
Year to date: −73.51%
1 year: −69.06%

Valuation & ownership

Market cap: 215.89M
Enterprise value: 19.90M
P/E (ttm): —
Forward P/E: -1.93
PEG ratio: —
Price / book: 0.88
Price / sales (ttm): —
EV / EBITDA: -0.21
EPS (ttm): -1.02
EPS (forward): -1.36
Beta (5y monthly): 1.64
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 82.09M
Float: 51.21M
Short % of float: 27.35%
Short ratio (days): 13.91
Held by insiders: 0.64%
Held by institutions: 114.66%
Avg volume (3m): 1.22M
50-day average: 4.26
200-day average: 5.63
52-week change: −69.06%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): oversold 22.0
vs 50-day SMA: −37.69%
vs 200-day SMA: −53.00%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 10.26%
Realised vol (20d, ann.): 80.1%
From 52-week high: −76.07%
From 52-week low: +2.73%

ANR

Analyst Consensus

10 analysts

Consensus

Strong buy

1.20 on a 1 (strong buy) – 5 (sell) scale

Mean target

20.30

+671.86% implied

Low 9.00Median 20.00High 30.00

Recommendation trend

Now10 / 0 / 0
1m ago10 / 0 / 0

DES

About Lexeo Therapeutics, Inc.

Yahoo Finance profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 63
Headquarters: New York, NY, United States

SEAS

Seasonality · LXEO

2023–2026 · monthly returns

Strongest month Jun +22.12%Weakest month Feb −31.02%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-25.4	-3.1	-20.1	-0.8	-9.7	-9.4	-11.3	15.3	-29.0	-22.2			−73.5%
2025	-17.5	-47.3	21.3	13.3	-30.8	47.8	17.7	1.3	38.6	50.8	-1.5	0.7	+50.9%
2024	27.7	-14.7	7.3	-20.6	33.6	-3.5	-21.8	-8.3	-21.5	-12.6	4.2	-20.0	−51.0%
2023												5.5	+5.5%

INSD

Insider Activity · LXEO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

153.2K shares

Sells, 6 months

71K shares

Net shares

+82.2K

Net change in insider shares

+18.70%

Date	Insider	Transaction	Shares	Value
Sep 13, 2026	Townsend Richard NolanChief Executive Officer	Stock Award(Grant) at price 4.21 per share.	2.3K	$9.71K
Sep 13, 2026	Otero Jose ManuelChief Operating Officer	Stock Award(Grant) at price 4.21 per share.	2.1K	$8.88K
Sep 13, 2026	Bhalla Narinder PalOfficer	Stock Award(Grant) at price 3.58 per share.	2.7K	$9.71K
Aug 17, 2026	Townsend Richard NolanChief Executive Officer	Sale at price 4.95 per share.	3.3K	$16.56K
Aug 17, 2026	Otero Jose ManuelChief Operating Officer	Sale at price 4.96 per share.	1.3K	$6.46K
Aug 17, 2026	Tamayo Louis EdwardChief Financial Officer	Sale at price 4.91 per share.	4.1K	$20.20K
Jun 30, 2026	Townsend Richard NolanChief Executive Officer	Sale at price 4.48 per share.	25.9K	$116.24K
Jun 30, 2026	Otero Jose ManuelChief Operating Officer	Sale at price 4.48 per share.	4.7K	$20.90K
Jun 30, 2026	Tamayo Louis EdwardChief Financial Officer	Sale at price 4.49 per share.	4.6K	$20.84K
Jun 30, 2026	Bhalla Narinder PalOfficer	Sale at price 4.42 per share.	22.3K	$98.59K
Jun 28, 2026	Townsend Richard NolanChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	67K	—
Jun 28, 2026	Otero Jose ManuelChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	12.1K	—
Jun 28, 2026	Tamayo Louis EdwardChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	12K	—
Jun 28, 2026	Bhalla Narinder PalOfficer	Stock Award(Grant) at price 0.00 per share.	55K	—
May 17, 2026	Townsend Richard NolanChief Executive Officer	Sale at price 5.06 per share.	3.3K	$16.93K
May 17, 2026	Otero Jose ManuelChief Operating Officer	Sale at price 5.07 per share.	1.3K	$6.61K
Apr 5, 2026	Townsend Richard NolanChief Executive Officer	Sale at price 5.69 per share.	55K	$313.14K
Mar 12, 2026	Townsend Richard NolanChief Executive Officer	Stock Award(Grant) at price 6.66 per share.	2.6K	$17.47K
Mar 12, 2026	Otero Jose ManuelChief Operating Officer	Stock Award(Grant) at price 6.66 per share.	5.9K	$39.49K
Feb 17, 2026	Townsend Richard NolanChief Executive Officer	Sale at price 6.38 per share.	10.2K	$64.92K

13F

Investors Holding LXEO

latest 13F filings of 29 followed managers

Investors holding LXEO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.2M	0.00%	250.37K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

LXEO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

LXEO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lexeo Therapeutics, Inc.

Seasonality · LXEO

Insider Activity · LXEO

Congress Trades · LXEO

Investors Holding LXEO

Investors Holding LXEO

Congress Trades · LXEO

Insider Activity · LXEO

Seasonality · LXEO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lexeo Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News